Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 344

Related Citations for PubMed (Select 17654304)

1.

Rapid and reversible modulation of platelet function in man by a novel P2Y(12) ADP-receptor antagonist, INS50589.

Johnson FL, Boyer JL, Leese PT, Crean C, Krishnamoorthy R, Durham T, Fox AW, Kellerman DJ.

Platelets. 2007 Aug;18(5):346-56.

PMID:
17654304
2.

Platelet inhibitory activity and pharmacokinetics of prasugrel (CS-747) a novel thienopyridine P2Y12 inhibitor: a multiple-dose study in healthy humans.

Matsushima N, Jakubowski JA, Asai F, Naganuma H, Brandt JT, Hirota T, Freestone S, Winters KJ.

Platelets. 2006 Jun;17(4):218-26.

PMID:
16769599
3.
4.

Pharmacokinetics and pharmacodynamics of a bolus and infusion of cangrelor: a direct, parenteral P2Y12 receptor antagonist.

Akers WS, Oh JJ, Oestreich JH, Ferraris S, Wethington M, Steinhubl SR.

J Clin Pharmacol. 2010 Jan;50(1):27-35. doi: 10.1177/0091270009344986. Epub 2009 Sep 24.

PMID:
19779037
5.

Platelet inhibitory activity and pharmacokinetics of prasugrel (CS-747) a novel thienopyridine P2Y12 inhibitor: a single ascending dose study in healthy humans.

Asai F, Jakubowski JA, Naganuma H, Brandt JT, Matsushima N, Hirota T, Freestone S, Winters KJ.

Platelets. 2006 Jun;17(4):209-17.

PMID:
16769598
6.
7.

Prevention of arterial thrombosis by intravenously administered platelet P2T receptor antagonist AR-C69931MX in a canine model.

Huang J, Driscoll EM, Gonzales ML, Park AM, Lucchesi BR.

J Pharmacol Exp Ther. 2000 Nov;295(2):492-9.

9.

Prostacyclin receptor stimulation facilitates detection of human platelet P2Y(12) receptor inhibition by the PFA-100 system.

Kobsar AL, Koessler J, Rajkovic MS, Brunner KP, Steigerwald U, Walter U.

Platelets. 2010;21(2):112-6. doi: 10.3109/09537100903440937.

PMID:
20085435
10.
11.

Prospective double-blind randomized study of the effects of four intravenous fluids on platelet function and hemostasis in elective hip surgery.

Evans PA, Heptinstall S, Crowhurst EC, Davies T, Glenn JR, Madira W, Davidson SJ, Burman JF, Hoskinson J, Stray CM.

J Thromb Haemost. 2003 Oct;1(10):2140-8.

PMID:
14521596
12.

Functional variability of platelet response to clopidogrel correlates with P2Y(12) receptor occupancy.

Bal Dit Sollier C, Berge N, Boval B, Hovsepian L, Drouet L.

Thromb Haemost. 2009 Jan;101(1):116-22.

PMID:
19132197
14.

Clopidogrel versus prasugrel in rabbits. Effects on thrombosis, haemostasis, platelet function and response variability.

Wong PC, Crain EJ, Watson CA, Hua J, Schumacher WA, Rehfuss R.

Thromb Haemost. 2009 Jan;101(1):108-15.

PMID:
19132196
16.

MK-383 (L-700,462), a selective nonpeptide platelet glycoprotein IIb/IIIa antagonist, is active in man.

Peerlinck K, De Lepeleire I, Goldberg M, Farrell D, Barrett J, Hand E, Panebianco D, Deckmyn H, Vermylen J, Arnout J.

Circulation. 1993 Oct;88(4 Pt 1):1512-7.

PMID:
8403299
17.
18.

Pharmacokinetics and pharmacodynamics of MK-383, a selective non-peptide platelet glycoprotein-IIb/IIIa receptor antagonist, in healthy men.

Barrett JS, Murphy G, Peerlinck K, De Lepeleire I, Gould RJ, Panebianco D, Hand E, Deckmyn H, Vermylen J, Arnout J.

Clin Pharmacol Ther. 1994 Oct;56(4):377-88.

PMID:
7955799
19.

The reversible P2Y antagonist cangrelor influences the ability of the active metabolites of clopidogrel and prasugrel to produce irreversible inhibition of platelet function.

Dovlatova NL, Jakubowski JA, Sugidachi A, Heptinstall S.

J Thromb Haemost. 2008 Jul;6(7):1153-9. doi: 10.1111/j.1538-7836.2008.03020.x. Epub 2008 Jul 1.

PMID:
18485086
20.

Preclinical and clinical studies with selective reversible direct P2Y12 antagonists.

van Giezen JJ, Humphries RG.

Semin Thromb Hemost. 2005 Apr;31(2):195-204. Review.

PMID:
15852223
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk